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lular	 carcinoma	 (HCC)	development.	We	aimed	 to	compare	 the	prognostic	ability	of	












spectively.	 The	 PAGE-	B	 event	 risk	 assessment	 improved	modestly	 when	 combined	
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However,	this	procedure	is	associated	with	potentially	severe	compli-
cations,	sampling	error,	as	well	as	inter-	and	intra-	observer	variation.6,7 
Noninvasive	 objective	 surrogate	 scores	 for	 the	 long-	term	 prognosis	
are	therefore	warranted.








Asian	 patients.13-18	 It	 is	 unknown	how	 the	 prognostic	 accuracy	 of	
these	noninvasive	serum	scores	compares	to	that	of	liver	histology	
with	respect	to	the	long-	term	outcome	in	CHB	patients,	especially	
with	 regard	 to	 event-	free	 and	 transplant-	free	 survival.	 Also,	 the	
prognostic	benefit	 in	performing	a	liver	biopsy	in	addition	to	these	
noninvasive	 scores	 has,	 to	 our	 knowledge,	 not	 been	 assessed	 in	
detail.




2  | MATERIALS AND METHODS
2.1 | Patient selection
The	 patient	 population	 and	 selection	 have	 been	 described	 previ-
ously.19	 In	short,	mono-	infected	treatment-	naïve	CHB	 (HBsAg	posi-
tive	 for	>6	months)	patients	consecutively	biopsied	 in	 the	period	of	




immunodeficiency	 virus,	 presence	of	 autoimmune	 liver	disease,	 pri-









cord	 database,	 and	 the	 development	 of	 HCC	was	 obtained	 from	
the	national	HCC	registry	database.	The	event	of	liver	transplanta-
tion	or	decompensation	was	obtained	 from	the	 (electronic)	medi-
cal	 chart.	Data	on	demographics	 (sex,	 age,	 race,	ethnicity,	height,	
weight,	 route	 of	 hepatitis	 B	 virus	 (HBV)	 transmission,	 presumed	
date	 of	 infection)	 and	 clinical	 data	 (history,	 diagnosis	 of	 diabetes	
mellitus,	 daily	 alcohol	 intake,	 history	 of	 alcohol	 abuse,	 smoking)	




chemistry	 (alanine	 aminotransferase	 [ALT],	 aspartate	 aminotrans-
ferase	 [AST],	 gamma-	glutyltransferase	 [y-	GT],	 bilirubin,	 albumin),	
haematology	 (platelet	 count,	 prothrombin	 time)	 and	 virology	
(HBsAg,	 anti-	HBs,	 hepatitis	 B	 e	 antigen	 [HBeAg],	 anti-	HBe,	HBV	





rescored	 by	 a	 single	 experienced	 hepato-	pathologist	 (FK)	who	was	




of	macrovesicular	 or	microvesicular	 steatosis,	 lobular	 inflammation,	
lipogranulomas	 and	 ballooning	 degeneration.22	 Advanced	 fibrosis	
was	defined	as	an	Ishak	score	of	≥4,	corresponding	to	portal	to	portal	





The	 gender	 and	 time-	dependent	 upper	 limit	 of	 normal	 values	were	
used	for	the	analysis	of	serum	ALT	and	AST.	The	HBV	DNA	level	was	






The	 occurrence	 of	 liver	 failure	 (defined	 as	 an	 episode	 of	 jaundice,	




of	multiple	 events	 in	 an	 individual	 patient,	 only	 the	 first	 event	was	
considered	for	the	composite	endpoint.	The	cause	of	death	was	de-
termined	by	 the	 treating	physician.	Death	caused	by	 liver	 failure	or	
HCC	was	considered	 liver-	related.	The	diagnosis	of	HCC	was	based	
on	 histopathology	 and	when	 not	 available,	 on	 two	 imaging	modali-
ties	(magnetic	resonance	imaging,	computed	tomography	or	contrast	
enhanced	ultrasound).25
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2.6 | Statistical analysis
Baseline	was	defined	as	the	date	of	first	liver	biopsy.	Scores	for	cir-
rhosis	 and	 outcome	 were	 constructed	 as	 previously	 described	 and	
their	respective	cut-	offs	were	utilized	in	the	analysis	when	appropri-












regression	model	 using	 the	 noninvasive	 risk	 score	with	 the	 highest	
overall C-	statistic.







univariable	Cox	 regression	model	 using	 the	 noninvasive	 risk	 score	
with	 the	 highest	 overall	 C-	statistic.	 After	 addition	 of	 liver	 biopsy	
characteristics	to	the	Cox	regression	model,	we	re-	assessed	the	up-
dated	C-	statistic	and	the	updated	estimation	of	this	event	risk	using	






version	22.0	 (SPSS	 Inc.,	Chicago,	 IL,	USA)	and	 the	SAS	9.3	program	
(SAS	 Institute	 Inc.,	 Cary,	NC,	USA)	were	 used	 to	 perform	 statistical	
analyses.	All	statistical	tests	were	two-	sided	and	evaluated	at	the	.05	
level	of	significance.
2.7 | Role of the funding source
Financial	 support	 was	 provided	 by	 the	 Foundation	 for	 Liver	 and	
Gastrointestinal	Research	 (SLO)	 in	Rotterdam,	 the	Netherlands,	 and	
by	 the	Virgo	 consortium,	 funded	by	 the	Dutch	 government	 project	
number	 FES0908,	 and	 by	 the	 NGI	 project	 number	 050-	060-	452.	






Of	880	biopsied	CHB	patients,	 163	did	not	meet	 eligibility	 criteria,	
127	were	 excluded	 because	 of	 a	missing	 chart	 or	 liver	 biopsy	 and	
33	were	excluded	because	of	an	 inadequate	 liver	biopsy	sample.	 In	
total,	557	patients	were	thus	included,	of	which	371	(67%)	were	male.	







more	often	HBeAg-	positive	 (66%	vs	25%,	P<.001),	had	higher	 log10 
HBV	DNA	 load	 (6.8	 [2.2]	vs	3.9	 [2.8]	 IU/mL,	P<.001),	ALT	and	AST	
(both	P<.01),	had	 lower	thrombocyte	counts	 (P<.001)	and	had	more	
often	advanced	liver	disease	(26%	vs	12%,	P<.001).
3.2 | Events during follow- up
The	mean	duration	of	follow-	up	after	liver	biopsy	was	10.1	years	(in-
terquartile	 range	 5.7-	15.9,	maximum	27.3	years).	 Survival	 and	HCC	
status	was	available	for	515	(92.6%)	patients,	and	41	(7.2%)	patients	
emigrated	 and	were	 censored	 at	 the	 last	 follow-	up	 visit;	 follow-	up	
data	of	one	patient	(0.2%)	could	not	be	retrieved.	Fifty-	one	patients	
lost	HBsAg	(median	time	from	biopsy	3.1	years,	IQR	1.2-	8.2,	maximum	
19.2	years).	 During	 long-	term	 follow-	up,	 40	 patients	 experienced	 a	
Risk score Components Cut- offs Ref




FIB-	4 Platelets,	age,	aspartate	aminotransferase	(AST),	ALT ≥3.25 9
Log	APRI Platelets,	AST >1.4 10
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3.3 | Factors associated with long- term 
clinical outcome
Fifty-	five	per	cent	(22/40)	of	all	patients	with	an	event	had	advanced	
fibrosis	 at	 baseline.	 The	 (non-	)invasive	 scores	were	 all	 significantly	
associated	with	the	development	of	a	clinical	event,	HCC	and	a	re-











mellitus	 (HR	5.7,	 95%	CI:	 2.7-	11.6,	P<.001)	 and	 alcohol	 abuse	 (HR	
4.4,	95%	CI:	1.8-	10.7,	P=.001)	were	also	associated	with	an	adverse	
clinical	outcome.
By	multivariable	 analysis,	 factors	 independently	 associated	with	
clinical	outcome	were	the	PAGE-	B	score	 (HR	1.27,	95%	CI:	1.2-	1.4,	
P<.001)	and	the	Ishak	fibrosis	stage	(HR	1.38,	95%	CI:	1.1-	1.7,	P=.003).
3.4 | Noninvasive scores vs liver biopsy for the 
prediction of clinical outcome
The	C-	statistic	for	the	PAGE-	B	score	for	the	prediction	of	any	clini-





prediction	 for	 any	 clinical	 event	 improved	 (C-	statistic	 .87,	95%	CI:	
0.82-	0.93).	For	PAGE-	B	 scores	<10,	10-	17	and	>17,	 the	observed	




PAGE-	B	 score	 are	 shown	 in	Figure	2.	 For	 patients	with	 a	PAGE-	B	




3.5 | Performance of noninvasive risk scores for 
clinical outcome in subgroups
For	the	prediction	of	any	clinical	event,	the	PAGE-	B	had	the	over-
all	 highest	 C-	statistic	 compared	 to	 the	 other	 noninvasive	 scores	
TABLE  2 Patient	characteristics





































AVT,	 antiviral	 therapy;	NA,	 nucleos(t)ide	 analogue;	 (Peg)IFN,	 (pegylated)	
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stratified	by	AVT,	advanced	fibrosis	and	ethnicity	(Table	4).	Within	
patients	with	 advanced	 fibrosis	 or	Asian	 patients,	 the	C-	statistics	
were	 comparable	 to	 the	 FIB-	4	 and	 REACH-	B,	 respectively.	 The	
C-	statistics	 obtained	with	 the	 PAGE-	B	 for	 the	 prediction	 of	HCC	
development	 in	 Asian	 patients	 who	 received	 AVT	 after	 liver	 bi-
opsy	was	 higher	 than	 the	 REACH-	B:	 this	was	 .75	 (95%	CI:	 0.53-	
0.97)	for	the	PAGE-	B	vs	.69	(95%	CI:	0.61-	0.78)	for	the	REACH-	B,	
respectively.
3.6 | Additional prognostic value of the Ishak stage 
combined with PAGE- B
The	 individual	 risk	of	 any	event	 for	patients	was	estimated	 for	 the	




and	nonevents	at	5-	and	10-	year	 intervals	 to	obtain	 the	NRI.	With	
the	addition	of	the	Ishak	fibrosis	stage,	two	of	12	(16.7%)	of	events	
were	 correctly	 reclassified	 into	 the	 intermediate-to-high	 risk	 group	
(PAGE-	B	score	>10,	corresponding	to	a	5-	year	event	risk	≥0.7%),	and	
three	of	430	(0.7%)	were	incorrectly	reclassified	into	the	intermedi-















for	 their	 ability	 to	 predict	 the	 clinical	 outcome	 over	 more	 than	






fied	by	AVT,	or	 among	 subgroups	of	 different	 ethnicity	 and	 sever-




Since	 timely	 diagnosis	 of	 severe	 liver	 disease	 may	 improve	 pa-
tients’	 prognosis	 through	 treatment	with	 highly	 potent	AVT,	 it	 is	 of	
great	 importance	 to	 select	 those	 patients	 in	 need	 for	 intervention	
and	parallel	HCC	surveillance	by	assessing	the	risk	of	clinical	disease	














among	 treated	Asian	 patients	 compared	 to	 the	REACH-	B.	The	vali-
dated	PAGE-	B	score	was	previously	constructed	in	a	selected	group	
Biomarker C- statistic 






PAGE-	B .86 (0.80-0.92) .83 (0.76-0.91) .91 (0.82-0.99)
REACH-	B .70	(0.59-	0.81) .66	(0.53-	0.80) .83	(0.75-	0.92)
FIB-	4 .79	(0.69-	0.89) .76	(0.65-	0.88) .86	(0.75-	0.98)
Log	APRI .69	(0.58-	0.80) .65	(0.53-	0.78) .81	(0.70-	0.91)
Invasive
PAGE-	B	+	Ishak .87 (0.82-0.93) .84 (0.78-0.91) .92 (0.85-0.99)
GAG-	HCCa .82	(0.75-	0.89) .78	(0.70-	0.87) .91	(0.86-	0.96)
CU-	HCCa .73	(0.63-	0.84) .69	(0.55-	0.82) .84	(0.73-	0.95)
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of	Caucasian	CHB	patients	under	highly	potent	NA	therapy	only.17,18 









































PAGE-	B .83 (0.75-0.92) .91 (0.82-0.99) .81	(0.70-	0.93) .81 (0.72-0.91) .89 (0.82-0.96) .87 (0.75-0.99) .78 (0.58-0.98)
REACH-	B .73	(0.62-	0.85) .66	(0.46-	0.86) .65	(0.49-	0.82) .65	(0.46-	0.84) .71	(0.57-	0.85) .87 (0.77-0.98) .49	(0.23-	0.76)
FIB-	4 .79	(0.69-	0.88) .77	(0.53-	0.99) .82 (0.70-0.93) .65	(0.47-	0.83) .83	(0.73-	0.92) .81	(0.67-	0.96) .61	(0.24-	0.99)




.85 (0.78-0.92) .90 (0.81-0.99) .82 (0.73-0.92) .79 (0.69-0.89) .88 (0.81-0.95) .94	(0.87-	0.99) .80 (0.62-0.98)
GAG-	HCCa .83	(0.76-	0.90) .82	(0.70-	0.94) .71	(0.58-	0.83) .74	(0.62-	0.86) .79	(0.70-	0.88) .97 (0.94-0.99) .68	(0.46-	0.91)
CU-	HCCa .78	(0.68-	0.88) .67	(0.46-	0.88) .77	(0.64-	0.90) .52	(0.36-	0.68) .68	(0.54-	0.82) .95	(0.90-	0.99) .61	(0.28-	0.94)
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For	decades,	the	gold	standard	to	assess	the	severity	of	liver	dis-
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